We are Sorry, This Page doesn't Exist
Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock
Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $.....»»
Alexion to acquire Portola Pharmaceuticals for $18 per share in cash
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Alexion to acquire Portola Pharmaceuticals for $18 per share in cash
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Aerie Pharmaceuticals to acquire Avizorex Pharma, S.L. in all-cash deal
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Aerie Pharmaceuticals to acquire Avizorex Pharma, S.L. in all cash deal
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Belgium"s UCB to acquire Ra Pharma in cash deal valued at about $2.5 billion
Belgian biopharma company UCB has agreed to acquire Ra Pharmaceuticals Inc. in a cash deal valued at about $2.5 billion, the companies said Thursday. Ra Pharma shareholders will receive $48 per sha.....»»
Amgen to acquire Otezla from Celgene for $13.4B in cash
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Amgen to acquire Otezla from Celgene for $13.4B in cash
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
P&G to buy German Merck"s consumer health business for about $4.21 billion
(Reuters) - Procter & Gamble Co agreed to acquire the consumer health business of German pharmaceuticals company Merck KGaA for about 3.4 billion euros ($4.21 billion) in cash, the companies said on Thursday......»»
Bristol-Myers to acquire Celgene in cash-and-stock deal with equity value of about $74 billion
Bristol Myers-Squibb Co. and Celgene Corp. said Thursday they have agreed to merge in a deal in which Bristol-Myers will acquire Celgene for cash and stock.....»»
Bristol-Myers, Celgene to Tie a $74 Billion Knot
Bristol-Myers has announced a definitive agreement to acquire rival Celgene in a cash and stock deal worth $74 billion. Celgene shareholders are scheduled to receive a 54% premium to Wednesday........»»
Bristol-Myers to acquire Celgene in year’s first major pharma deal
Manhattan-based Bristol-Myers Squibb is buying fellow drugmaker Celgene in a cash and stock deal valued at $74 billion, with Bristol-Myers’ shareholders expected to own 69% of the combined entity. ["> To view the full story, click the title link......»»
Bristol-Myers to acquire Celgene in year’s first major pharma deal
Manhattan-based Bristol-Myers Squibb is buying fellow drugmaker Celgene in a cash and stock deal valued at $74 billion, with Bristol-Myers’ shareholders expected to own 69% of the combined entity.... To view the full story, click the title link......»»
H&E Equipment to acquire We-Rent-It for approx. $100M in cash
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Ipsen to acquire Clementia Pharmaceuticals for $25.00 per share in cash upfront
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Ipsen to acquire Clementia Pharmaceuticals for $25.00 per share in cash upfront
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. Latest Ratings for INCY DateFirmActio.....»»
Marinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidate
Marinus Pharmaceuticals said it will implement cost-cutting measures to extend its cash runway beyond the fourth quarter of 2024......»»
Group 1 Makes Power Move in UK Market with Inchcape Auto Dealerships Buy Out
Group 1 Automotive to acquire Inchcape's U.K. dealerships for $439M in all-cash deal. Deal expected to close in Q3 2024. read more.....»»
Xeris Pharmaceuticals to acquire Strongbridge Biopharma for $267M in stock, CVRs
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»